Osteoprotegerin as a marker of atherosclerosis: A systematic update

Scandinavian Cardiovascular Journal

Volumn 46, Issue 4, 2012, Pages 203-211

  Hosbond, Susanne Elisabeth ^a   Poulsen, Tina Svenstrup ^a   Diederichsen, Axel Cosmus Pyndt ^a   Nybo, Mads ^a   Rasmussen, Lars Melholt ^a   Mickley, Hans ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Atherosclerosis; Coronary artery disease; Osteoprotegerin

Indexed keywords

BIOLOGICAL MARKER; OSTEOPROTEGERIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANALYTICAL EQUIPMENT; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR DISEASE; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; HUMAN; MEDLINE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; RISK ASSESSMENT;

EID: 84863789858     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2012.685491     Document Type: Review

References (36)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, L üthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89: 309-19.
2. Brown SA, Rosen CJ. Osteoporosis. Med Clin North Am. 2003;87:1039-63.
3. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KBJM, Geusens PPM, Kitslaar PJEHM, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
4. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O ' Brien T, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Comm. 2001;280:334-9.
5. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: Increased amounts in diabetes and modifi able synthesis from vascular smooth muscle cells by insulin and TNF. Diabetologia. 2005;48:561-8.
6. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549-53.
7. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. Eur J Endocrin. 2008;159:603-8.
8. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-k B and osteoprotegerin expression by human microvascular endothelial cells, regulation by infl ammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001;276:20659-72.
9. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-5.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-defi cient mice develop early onset osteoporosis and arterial calcifi cation. Genes Dev. 1998;12:1260-8.
11. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcifi cation in older ApoE -/- mice. Arterioscler Thromb Vasc Biol. 2006; 26:2117-24.
12. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, et a l. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106: 1192-4.
13. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-8.
14. Rhee E, Lee W, Kim S, Kim BJ, Sung KC, Kim BS, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci 2005.;108:237-43.
15. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci. 2005;109:389-95.
16. Vik A, Mathiesen EB, Notø ATW, Sveinbj ør nsson B, Brox J, Hansen JB. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis. 2007;191:128-34.
17. Kadoglou NPE, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, Liapis CD. The relationship between serum levels of vascular calcifi cation inhibitors and carotid plaque vulnerability. J Vasc Surg. 2008;47:55-62.
18. Sandberg WJ, Yndestad A, Ø i e E, Smith C, Ueland T, Ovchinnikova O, et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: Possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26: 857-63.
19. Palazzuoli A, Rizzello V, Calabró A, Gallotta M, Martini G, Quatrini I, et al. Osteoprotegerin and B-type natriuretic peptide in non-ST elevation acute coronary syndromes: Relation to coronary artery narrowing and plaques number. Clin Chim Acta. 2008;391:74-9.
20. Ren MY, Sui SJ, Zhang Y, Xu FY, Xu XQ, Zhao JJ, et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol. 008;63:615-22.
21. Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int. 2004;15:389-95.
22. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with the severity of peripheral artery disease. Atherosclerosis. 2005;182:175-80.
23. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P; Willvonsedera R for the Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003;32:681-6.
24. Koshikawa M, Aizawa K, Kasai H, Izawa A, Tomita T, Kumazaki S, et al. Elevated osteopontin levels in patients with peripheral arterial disease. Angiology. 2009;60:42-5.
25. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, et al. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res. 2007;120:511-6.
26. st ündag M, Orak M, Güloglu C, Tamam Y, Sayhan MB, Kale E. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: Determination of stroke subtype, severity and mortality. J Int Med Res. 2011;39:780-9.
27. Grogan JK, Shaalan WE, Cheng H, Gewertz B, Desai T, Schwarze G, et al. B-mode ultrasonographic characterization of carotid atherosclerotic plaques in symptomatic and asymptomatic patients. J Vasc Surg. 2005;42:435-41.
28. Chan BY, Buckley KA, Durham BH, Gallagher JA, Fraser WD. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem. 2003;49:2083-5.
29. Jono S, Otsuki S, Higashikuni Y, Shioi A, Mori K, Hara K, et al. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost. 2010;8:1170-5.
30. Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med. 2010;267:410-7.
31. Vik A, Mathiesen EB, Johnsen SH, Brox J, Wilsgaard T, Nj ø lstad I, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population-the Troms ø study. J Thromb Haemost. 2010;8:898-905.
32. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia. 2008;51:2100-7.
33. Reinhard H, Lajer M, Gall MA, Tarnow L, Parving HH, Rasmussen LM, et al. Osteoprotegerin and Mortality in Type 2 Diabetic Patients. Diabetes Care. 2010;33:2561-6.
34. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA, et al. Coronary calcifi cation in hemodialysis patients: The contribution of traditional and uremia-related risk factors. Kidney Int. 2005;67:1576-82.
35. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010; 55:2049-61.
36. Nybo M, Rasmussen LM. Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis. 2008;201:33-5.